45 completed, 5 terminated, 4 active not recruiting, 3 recruiting. 62 Phase 3, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 62 | Completed 45, Terminated 5, Active not recruiting 4, Recruiting 3, Unknown 2, Withdrawn 2, Not yet recruiting 1 |
| Phase 2 | 10 | Completed 8, Terminated 1, Unknown 1 |
Follow Malabsorption Syndromes: new trials by email Literature Review of Malabsorption Syndromes trials Research Report on Malabsorption Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF) Apraglutide, Placebo - Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF) | Phase 3 | Recruiting | VectivBio AG | 124 | 2026-08-01 | 2026-08-04 |
| Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS Glepaglutide, Placebo - Short Bowel Syndrome | Phase 3 | Recruiting | Zealand Pharma | 90 | 2026-02-11 | 2026-09-29 |
| Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome Glepaglutide 10 mg - Short Bowel Syndrome (SBS) | Phase 3 | Active not recruiting | Zealand Pharma | 28 | 2025-12-11 | 2026-07-30 |
| A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome Teduglutide - Short Bowel Syndrome | Phase 3 | Active not recruiting | Takeda | 13 | 2025-06-26 | 2026-09-08 |
| Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants ELGN-2112, Placebo - Intestinal Malabsorption | Phase 3 | Recruiting | Elgan Pharma Ltd. | 360 | 2025-02-27 | 2026-01-23 |
| Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition PJ009, PJ009 Placebo - Short Bowel Syndrome | Phase 3 | Active not recruiting | Chongqing Peg-Bio Biopharm Co., Ltd. | 72 | 2024-09-03 | 2026-10-22 |
| Preventing Celiac Disease by Weaning With Mediterranean Diet Weaning by Mediterranean Diet - Weaning Failure | Phase 3 | Not yet recruiting | University of Naples | 3200 | 2024-06-15 | 2024-05-08 |
| A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older Teduglutide - Short Bowel Syndrome | Phase 3 | Completed | Takeda | 3 | 2022-01-04 | 2024-05-16 |
| The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome Glepaglutide - Short Bowel Syndrome | Phase 3 | Completed | Zealand Pharma | 12 | 2021-08-10 | 2024-11-22 |
| Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome. Apraglutide - Short Bowel Syndrome | Phase 3 | Active not recruiting | VectivBio AG | 158 | 2021-07-13 | 2025-07-02 |
| Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial Glepaglutide - Short Bowel Syndrome | Phase 3 | Completed | Zealand Pharma | 84 | 2021-06-16 | 2026-09-08 |
| Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IF apraglutide - Short Bowel Syndrome | Phase 3 | Completed | VectivBio AG | 164 | 2021-01-26 | 2024-11-27 |
| Assessment of the Effect of Gluten Free Toothpaste on the Ulcerative Events in Children With Celiac Disease experimental gluten free toothpaste - Gluten Sensitivity | Phase 3 | Completed | Cairo University | 20 | 2019-07-21 | 2020-07-21 |
| Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms Larazotide, Matching Placebo - Celiac Disease | Phase 3 | Terminated | 9 Meters Biopharma, Inc. | 307 | 2019-05-29 | 2022-07-26 |
| Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS glepaglutide - Short Bowel Syndrome | Phase 3 | Completed | Zealand Pharma | 150 | 2019-05-07 | 2026-09-08 |
| Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS) glepaglutide, Placebo - Short Bowel Syndrome | Phase 3 | Completed | Zealand Pharma | 106 | 2018-10-04 | 2025-07-17 |
| Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome Teduglutide, Standard Medical Therapy, Syringe - Short Bowel Syndrome | Phase 3 | Completed | Shire | 10 | 2018-08-31 | 2021-05-11 |
| An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004 Teduglutide, Syringe, Needle - Short Bowel Syndrome | Phase 3 | Completed | Takeda | 11 | 2018-07-09 | 2023-03-15 |
| Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Teduglutide, Syringe, Needle - Short Bowel Syndrome | Phase 3 | Completed | Shire | 7 | 2018-07-06 | 2020-08-04 |
| Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance RP-G28, Placebos - Lactose Intolerance | Phase 3 | Completed | Ritter Pharmaceuticals, Inc. | 557 | 2018-06-26 | 2019-07-08 |
Showing 20 of 62. Sign in to see all of them.
Short Bowel Syndrome (35) · Celiac Disease (7) · Hyperphagia (6) · Steatorrhea (5) · Cystic Fibrosis (4) · Exocrine Pancreatic Insufficiency (4) · Hyperhomocysteinemia (4) · Intestinal Failure (4) · Lactose Intolerance (4) · Cholestasis (3) · Gastrointestinal Diseases (3) · Abdominal Pain (2) · Digestive System Diseases (2) · Hypertension (2)
Digestive System Diseases (56) · Intestinal Diseases (56) · Gastrointestinal Diseases (55) · Pathological Conditions, Signs and Symptoms (38) · Pathologic Processes (33) · Postoperative Complications (33) · Metabolic Diseases (29) · Nutritional and Metabolic Diseases (29) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Genetic Diseases, Inborn (13) · Signs and Symptoms (10) · Signs and Symptoms, Digestive (10) · Metabolism, Inborn Errors (9) · Carbohydrate Metabolism, Inborn Errors (5)
teduglutide (16) · ALX-0600 (6) · Needles (4) · Syringes (4) · apraglutide (3) · fish oil triglycerides (3) · Glutens (2) · Lactase (2) · RP-G28 (2) · Amlodipine (1) · Contraceptives, Oral (1) · Diet, Gluten-Free (1) · Enalapril (1) · Glucagon-Like Peptide 2 (1) · Lidocaine (1)
Shire (14) · Zealand Pharma (6) · Elgan Pharma Ltd. (3) · Takeda (3) · VectivBio AG (3) · All India Institute of Medical Sciences (2) · Eurofarma Laboratorios S.A. (2) · Forest Laboratories (2) · Marathon Pharmaceuticals, LLC (2) · Ritter Pharmaceuticals, Inc. (2) · 9 Meters Biopharma, Inc. (1) · Abbott (1) · Cairo University (1) · Center for Health Sciences, Serbia (1) · Children's Hospital Medical Center, Cincinnati (1)
United States (32) · United Kingdom (17) · France (15) · Belgium (13) · Denmark (13) · Germany (13) · Poland (12) · Canada (11) · Italy (11) · Japan (9) · Netherlands (9) · Spain (7) · Israel (6) · Brazil (5) · China (5)
Heda Amarante, M.D (2) · Marta Machado, M.D (2) · Mauro Bafutto, M.D (2) · Sender Miszputen, M.D (2) · Tomasz Masior (2) · Wilson Catapani, M.D (2) · Aldo Lima, MD, PhD (1) · Anna Sapone, MD, PhD (1) · Beth Kirkpatrick, M.D. (1)
PMID 37364133, PMID 21317170, PMID 24134154, PMID 27507402, PMID 37889619, PMID 38873891, PMID 41858082, PMID 16099790, PMID 19661785, PMID 19829124, PMID 21791335, PMID 21975668, PMID 22752636, PMID 22982184, PMID 23274148, PMID 23333663, PMID 23587733, PMID 25987795, PMID 26643930, PMID 26870801, PMID 27154394, PMID 27217217, PMID 27706451, PMID 27855998, PMID 28293424, PMID 28444240, PMID 28627732, PMID 29174926, PMID 29390150, PMID 29394355, PMID 29514306, PMID 29761915, PMID 31784300, PMID 32059815, PMID 32157282, PMID 32341691, PMID 32826717, PMID 32867719, PMID 33038344, PMID 34365905, PMID 34565452, PMID 34695449, PMID 35226099, PMID 39052701, PMID 39708985, PMID 41454663, PMID 42861767
2004 (2), 2016 (2), 2008 (1), 2009 (1), 2017 (1), 2025 (1)